Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KALV
DateTimeSourceHeadlineSymbolCompany
02/05/202411:30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
01/05/202411:30Business WireKalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal YearNASDAQ:KALVKalVista Pharmaceuticals Inc
22/04/202411:30Business WireKalVista Pharmaceuticals Appoints William C. Fairey to Board of DirectorsNASDAQ:KALVKalVista Pharmaceuticals Inc
03/04/202411:30Business WireKalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:KALVKalVista Pharmaceuticals Inc
02/04/202411:30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
18/03/202410:30Business WireKalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference AmericasNASDAQ:KALVKalVista Pharmaceuticals Inc
12/03/202410:30Business WireKalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for SebetralstatNASDAQ:KALVKalVista Pharmaceuticals Inc
11/03/202420:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
11/03/202420:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KALVKalVista Pharmaceuticals Inc
11/03/202410:30Business WireKalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational UpdateNASDAQ:KALVKalVista Pharmaceuticals Inc
08/03/202421:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
08/03/202411:30Business WireKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasNASDAQ:KALVKalVista Pharmaceuticals Inc
07/03/202411:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
07/03/202411:30Business WireKalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive OfficerNASDAQ:KALVKalVista Pharmaceuticals Inc
06/03/202411:30Business WireKalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KALVKalVista Pharmaceuticals Inc
04/03/202411:30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
27/02/202411:30Business WireKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingNASDAQ:KALVKalVista Pharmaceuticals Inc
26/02/202411:30Business WireKalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingNASDAQ:KALVKalVista Pharmaceuticals Inc
22/02/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
22/02/202418:22Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:KALVKalVista Pharmaceuticals Inc
22/02/202402:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
22/02/202402:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
22/02/202402:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
22/02/202402:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
22/02/202402:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
20/02/202421:49Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:KALVKalVista Pharmaceuticals Inc
20/02/202411:30Business WireKalVista Pharmaceuticals Awarded UK Innovation Passport for SebetralstatNASDAQ:KALVKalVista Pharmaceuticals Inc
16/02/202421:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
16/02/202421:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KALVKalVista Pharmaceuticals Inc
16/02/202421:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:KALV